The United Laboratories (03933.HK): Marketing registration application for insulin degludec and liraglutide injection accepted

Zhitong Finance APP News, The United Group Pharmaceutical (03933.HK) announced that the marketing registration application for Insulin Degludec Liraglutide Injection (IDegLira), independently developed by the company's wholly-owned subsidiary Zhuhai United Biopharmaceutical Co., Ltd., has been accepted by China's National Medical Products Administration, with acceptance number CXSS2600154. The company is the first enterprise in China to submit a marketing registration application for an insulin degludec liraglutide biosimilar.